Rezultati pretrage - Enrico Cortesi

Detaljiziraj rezultate
  1. 1
    Clinical outcome and prognostic factors in renal medullary carcinoma. A pooled analysis from 18 years of medical literature.

    Clinical outcome and prognostic factors in renal medullary carcinoma. A pooled analysis from 18 years of medical literature. od Roberto Iacovelli, Daniela Modica, Antonella Palazzo, Patrizia Trenta, Gabriele Piesco, Enrico Cortesi

    Izdano 2015
    Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  2. 2
    Incidence and risk of pulmonary toxicity in patients treated with mTOR inhibitors for malignancy. A meta-analysis of published trials

    Incidence and risk of pulmonary toxicity in patients treated with mTOR inhibitors for malignancy. A meta-analysis of published trials od Roberto Iacovelli, Antonella Palazzo, Silvia Mezi, Federica Morano, Giuseppe Naso, Enrico Cortesi

    Izdano 2012
    Preuzmi cijeli tekst Preuzmi cijeli tekst
    Revisão
    Spremi u popis
    Spremljeno u:
  3. 3
    Molecular markers in circulating tumour cells from metastatic colorectal cancer patients

    Molecular markers in circulating tumour cells from metastatic colorectal cancer patients od Paola Gazzaniga, Angela Gradilone, Arianna Petracca, Chiara Nicolazzo, Cristina Raimondi, Roberto Iacovelli, Giuseppe Naso, Enrico Cortesi

    Izdano 2010
    Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  4. 4
    Incidence and relative risk of hepatic toxicity in patients treated with anti-angiogenic tyrosine kinase inhibitors for malignancy

    Incidence and relative risk of hepatic toxicity in patients treated with anti-angiogenic tyrosine kinase inhibitors for malignancy od Roberto Iacovelli, Antonella Palazzo, Giuseppe Procopio, Matteo Santoni, Patrizia Trenta, Angelina De Benedetto, Silvia Mezi, Enrico Cortesi

    Izdano 2013
    Preuzmi cijeli tekst
    Revisão
    Spremi u popis
    Spremljeno u:
  5. 5
    PD-L1 and epithelial-mesenchymal transition in circulating tumor cells from non-small cell lung cancer patients: A molecular shield to evade immune system<b>?</b>

    PD-L1 and epithelial-mesenchymal transition in circulating tumor cells from non-small cell lung cancer patients: A molecular shield to evade immune system<b>?</b> od Cristina Raimondi, Guido Carpino, Chiara Nicolazzo, Angela Gradilone, Walter Gianni, Alain Gelibter, Eugenio Gaudio, Enrico Cortesi, Paola Gazzaniga

    Izdano 2017
    Preuzmi cijeli tekst Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  6. 6
    Transient Disappearance of RAS Mutant Clones in Plasma: A Counterintuitive Clinical Use of EGFR Inhibitors in RAS Mutant Metastatic Colorectal Cancer

    Transient Disappearance of RAS Mutant Clones in Plasma: A Counterintuitive Clinical Use of EGFR Inhibitors in RAS Mutant Metastatic Colorectal Cancer od Cristina Raimondi, Chiara Nicolazzo, Francesca Belardinilli, Flavia Loreni, Angela Gradilone, Yasaman Mahdavian, Alain Gelibter, Giuseppe Giannini, Enrico Cortesi, Paola Gazzaniga

    Izdano 2019
    Preuzmi cijeli tekst Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  7. 7
    Circulating tumour cells lacking cytokeratin in breast cancer: the importance of being mesenchymal

    Circulating tumour cells lacking cytokeratin in breast cancer: the importance of being mesenchymal od Angela Gradilone, Cristina Raimondi, Chiara Nicolazzo, Arianna Petracca, Orietta Gandini, Bruno Vincenzi, Giuseppe Naso, Anna Maria Aglianò, Enrico Cortesi, Paola Gazzaniga

    Izdano 2011
    Preuzmi cijeli tekst Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  8. 8
    Chemotherapy of advanced non-small-cell lung cancer: A comparison of three active regimens. A randomized trial of the Italian Oncology Group for Clinical Research (G.O.I.R.C.)

    Chemotherapy of advanced non-small-cell lung cancer: A comparison of three active regimens. A randomized trial of the Italian Oncology Group for Clinical Research (G.O.I.R.C.) od Lucio Crinò, M. Clerici, F. Figoli, Paolo Carlini, Guido Ceci, Enrico Cortesi, A Carpi, Alessandra Santini, Francesco Di Costanzo, C. Boni

    Izdano 1995
    Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  9. 9
    Circulating Tumor Cells Identify Patients with Super-High-Risk Non-Muscle-Invasive Bladder Cancer: Updated Outcome Analysis of a Prospective Single-Center Trial

    Circulating Tumor Cells Identify Patients with Super-High-Risk Non-Muscle-Invasive Bladder Cancer: Updated Outcome Analysis of a Prospective Single-Center Trial od Chiara Nicolazzo, Gian Maria Busetto, Angela Gradilone, Isabella Sperduti, Francesco Del Giudice, Flavia Loreni, Enrico Cortesi, Ettore De Berardinis, Paola Gazzaniga, Cristina Raimondi

    Izdano 2019
    Preuzmi cijeli tekst Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  10. 10
    Monitoring PD-L1 positive circulating tumor cells in non-small cell lung cancer patients treated with the PD-1 inhibitor Nivolumab

    Monitoring PD-L1 positive circulating tumor cells in non-small cell lung cancer patients treated with the PD-1 inhibitor Nivolumab od Chiara Nicolazzo, Cristina Raimondi, M. Mancini, S Caponnetto, Angela Gradilone, Orietta Gandini, Maria Mastromartino, Gabriella Del Bene, Alessandra Anna Prete, Flavia Longo, Enrico Cortesi, Paola Gazzaniga

    Izdano 2016
    Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  11. 11
    nmCRPC, a look in the continuous care of prostate cancer patients: state of art and future perspectives

    nmCRPC, a look in the continuous care of prostate cancer patients: state of art and future perspectives od Alfredo Berruti, Sergio Bracarda, Orazio Caffo, Enrico Cortesi, Rolando Maria D’Angelillo, Marzia Del Re, Gaetano Facchini, Giovanni Pappagallo, Giuseppe Procopio, Roberto Sabbatini, Daniele Santini

    Izdano 2023
    Preuzmi cijeli tekst
    Revisão
    Spremi u popis
    Spremljeno u:
  12. 12
    Pre-treatment neutrophil-to-lymphocyte ratio may be associated with the outcome in patients treated with everolimus for metastatic renal cell carcinoma

    Pre-treatment neutrophil-to-lymphocyte ratio may be associated with the outcome in patients treated with everolimus for metastatic renal cell carcinoma od Matteo Santoni, Ugo De Giorgi, Roberto Iacovelli, Alessandro Conti, Luciano Burattini, Lorena Rossi, Salvatore Luca Burgio, Rossana Berardi, Giovanni Muzzonigro, Enrico Cortesi, D. Amadori, Stefano Cascinu

    Izdano 2013
    Preuzmi cijeli tekst Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  13. 13
    Immune effects of CDK4/6 inhibitors in patients with HR+/HER2− metastatic breast cancer: Relief from immunosuppression is associated with clinical response

    Immune effects of CDK4/6 inhibitors in patients with HR+/HER2− metastatic breast cancer: Relief from immunosuppression is associated with clinical response od Fabio Scirocchi, Simone Scagnoli, Andrea Botticelli, Alessandra Di Filippo, Chiara Napoletano, Ilaria Grazia Zizzari, Lidia Strigari, Federica Tomao, Enrico Cortesi, Aurelia Rughetti, Paolo Marchetti, Marianna Nuti

    Izdano 2022
    Preuzmi cijeli tekst Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  14. 14
    Circulating tumor cells (CTCs) in metastatic breast cancer (MBC): prognosis, drug resistance and phenotypic characterization

    Circulating tumor cells (CTCs) in metastatic breast cancer (MBC): prognosis, drug resistance and phenotypic characterization od Angela Gradilone, Giuseppe Naso, Cristina Raimondi, Enrico Cortesi, Orietta Gandini, Bruno Vincenzi, Rosa Saltarelli, E. Chiapparino, Franco Spremberg, Massimo Cristofanilli, Luigi Frati, Anna Maria Aglianò, Paola Gazzaniga

    Izdano 2010
    Preuzmi cijeli tekst Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  15. 15
    Epidermal Growth Factor Receptor Gene Copy Number and Clinical Outcome of Metastatic Colorectal Cancer Treated With Panitumumab

    Epidermal Growth Factor Receptor Gene Copy Number and Clinical Outcome of Metastatic Colorectal Cancer Treated With Panitumumab od Andrea Sartore‐Bianchi, Mauro Moroni, Silvio Veronese, Carlo Carnaghi, Emilio Bajetta, Gabriele Luppi, Alberto Sobrero, Carlo Barone, Stefano Cascinu, Giuseppe Colucci, Enrico Cortesi, Michele Nichelatti, Marcello Gambacorta, Salvatore Siena

    Izdano 2007
    Preuzmi cijeli tekst Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  16. 16
    Intermittent versus continuous chemotherapy in advanced colorectal cancer: a randomised ‘GISCAD’ trial

    Intermittent versus continuous chemotherapy in advanced colorectal cancer: a randomised ‘GISCAD’ trial od Roberto Labianca, Alberto F. Sobrero, L. Isa, Enrico Cortesi, Sandro Barni, Dario Nicolella, Massimo Aglietta, Sara Lonardi, Domenico Corsi, D. Turci, Giordano Beretta, Giuseppe Fornarini, E. Dapretto, Irene Floriani, Alberto Zaniboni

    Izdano 2010
    Preuzmi cijeli tekst Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  17. 17
    Adjuvant Chemotherapy in Completely Resected Gastric Cancer: A Randomized Phase III Trial Conducted by GOIRC

    Adjuvant Chemotherapy in Completely Resected Gastric Cancer: A Randomized Phase III Trial Conducted by GOIRC od Francesco Di Costanzo, Silvia Gasperoni, L. Manzione, Giancarlo Bisagni, Roberto Labianca, Stefano Bravi, Enrico Cortesi, Paolo Carlini, R. Bracci, Federica Tomao, Luca Messerini, Annarosa Arcangeli, Valter Torri, D. Bilancia, Irene Floriani, Maurizio Tonato

    Izdano 2008
    Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  18. 18
    The role of opioids in cancer response to immunotherapy

    The role of opioids in cancer response to immunotherapy od Andrea Botticelli, Alessio Cirillo, Giulia Pomati, Bruna Cerbelli, Simone Scagnoli, Michela Roberto, Alain Gelibter, Giulia Mammone, Maria Letizia Calandrella, Edoardo Cerbelli, Francesca Romana Di Pietro, Federica De Galitiis, Gaetano Lanzetta, Enrico Cortesi, Silvia Mezi, Paolo Marchetti

    Izdano 2021
    Preuzmi cijeli tekst Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  19. 19
    Phase III Trial of Infusional Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan (FOLFOXIRI) Compared With Infusional Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) As First-Line Treatment for Metastatic Colorectal Cancer: The Gruppo Oncologico Nord Ovest

    Phase III Trial of Infusional Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan (FOLFOXIRI) Compared With Infusional Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) As First... od Alfredo Falcone, Sergio Ricci, I. Brunetti, E. Pfanner, Giacomo Allegrini, C. Barbara, Lucio Crinò, Giovanni Benedetti, W. Evangelista, Laura Fanchini, Enrico Cortesi, V. Picone, S. Vitello, Silvana Chiara, Cristina Granetto, Gianfranco Porcile, Luisa Fioretto, Cinzia Orlandini, M. Andreuccetti, Gianluca Masi

    Izdano 2007
    Preuzmi cijeli tekst Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  20. 20
    Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer

    Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer od Fotios Loupakis, Chiara Cremolini, Gianluca Masi, Sara Lonardi, Vittorina Zagonel, Lisa Salvatore, Enrico Cortesi, Gianluca Tomasello, M. Ronzoni, Rosella Spadi, Alberto Zaniboni, Giuseppe Tonini, Angela Buonadonna, D. Amoroso, Silvana Chiara, Chiara Carlomagno, C. Boni, Giacomo Allegrini, Luca Boni, Alfredo Falcone

    Izdano 2014
    Preuzmi cijeli tekst Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:

Alati za pretragu: